Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia
2022-502782-14-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing MK-0616 with Placebo (2 arms). Primary endpoints: Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24, Number of participants with one or more adverse events (AEs) and 1 more. Started Sep 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2022-502782-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502782-14-00.